| Literature DB >> 26260579 |
Sarah L Jones1, Aiko Tanaka2, Glenn M Eastwood3,4, Helen Young5, Leah Peck6, Rinaldo Bellomo7,8, Johan Mårtensson9,10.
Abstract
INTRODUCTION: Assessment of fluid status in critically ill patients is challenging. We aimed to assess the feasibility and validity of bioelectrical impedance vector analysis (BIVA) as a measure of hydration in critically ill patients.Entities:
Mesh:
Year: 2015 PMID: 26260579 PMCID: PMC4531396 DOI: 10.1186/s13054-015-1009-3
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Examples of values obtained with the Renal EFG BIVA™ Technology. BIVA bioelectrical impedance vector analysis, H height, PA phase angle, Xc reactance, BCM body cell mass
Fig. 2Selection of study patients. BIVA bioelectrical impedance vector analysis, ICU intensive care unit
Baseline characteristics of the study cohort, stratified by hydration level according to bioelectrical impedance vector analysis measurement upon admission
| All | Dehydration | Normal | Overhydration |
| |
|---|---|---|---|---|---|
| ( | ( | ( | ( | ||
| Age, yr | 63 (48–72) | 66 (56–76) | 61 (43–68) | 65 (52–75) | 0.43 |
| Female sex, | 23 (38 %) | 5 (38 %) | 11 (50 %) | 7 (28 %) | 0.30 |
| Height, cm | 168 (158–175) | 168 (160–170) | 169 (158–175) | 173 (159–178) | 0.77 |
| Weight, kg | 76 (67–96) | 75 (64–85) | 74 (67–88) | 90 (72–109) | 0.16 |
| Body mass index, kg/m2 | 28 (24–33) | 26 (24–29) | 27 (23–30) | 29 (25–36) | 0.22 |
| APACHE III score | 62 (47–82) | 75 (49–82) | 53 (45–67) | 72 (48–92) | 0.21 |
| Time from ICU admission until enrolled, h | 14 (7–19) | 11 (5–19) | 11 (4–19) | 15 (12–19) | 0.23 |
| Comorbidity | |||||
| Cardiovascular, | 26 (43 %) | 4 (29 %) | 11 (50 %) | 11 (44 %) | 0.51 |
| COPD/asthma, | 8 (13 %) | 5 (38 %) | 0 (0) | 3 (12 %) | 0.007 |
| Diabetes mellitus, | 16 (26 %) | 1 (7 %) | 5 (23 %) | 10 (40 %) | 0.08 |
| Chronic liver disease, | 8 (13 %) | 1 (7 %) | 0 (0) | 7 (28 %) | 0.009 |
| Neurological, | 3 (5 %) | 1 (7 %) | 1 (5 %) | 1 (4 %) | 1.0 |
| Chronic kidney disease, | 4 (7 %) | 1 (7 %) | 0 (0) | 3 (12 %) | 0.27 |
| Malignancy, | 9 (15 %) | 3 (21 %) | 3 (14 %) | 3 (12 %) | 0.74 |
| Non-operative admission diagnosis | |||||
| Sepsis, | 10 (16 %) | 4 (29 %) | 4 (18 %) | 2 (8 %) | 0.24 |
| Cardiac, | 8 (13 %) | 4 (29 %) | 2 (9 %) | 2 (8 %) | 0.21 |
| Neurological, | 9 (15 %) | 1 (7 %) | 5 (23 %) | 3 (12 %) | 0.47 |
| Respiratory, | 9 (15 %) | 3 (21 %) | 6 (27 %) | 0 (0) | 0.01 |
| Intoxication, | 2 (3 %) | 0 (0) | 1 (5 %) | 1 (4 %) | 1.0 |
| Liver, | 2 (3 %) | 0 (0) | 0 (0) | 2 (8 %) | 0.34 |
| Gastrointestinal, | 5 (8 %) | 0 (0) | 0 (0) | 5 (20 %) | 0.02 |
| Operative admission diagnosis | |||||
| Neurological, | 3 (5 %) | 1 (7 %) | 0 (0) | 2 (8 %) | 0.44 |
| Vascular, | 2 (3 %) | 0 (0) | 1 (5 %) | 1 (4 %) | 1.0 |
| Gastrointestinal, | 11 (18 %) | 1 (7 %) | 3 (14 %) | 7 (28 %) | 0.27 |
APACHE III Acute Physiology and Chronic Health Evaluation III, BIVA bioelectrical impedance vector analysis, COPD chronic obstructive pulmonary disease
Continuous variables are presented as median (interquartile range)
aStatistical comparisons of the data were performed using the χ2 test or Fisher’s exact test for categorical variables and the Kruskal-Wallis test for continuous variables
Admission bioelectrical impedance vector analysis data, haemodynamics, oxygen exchange and biochemical data
| Dehydration | Normal | Overhydration |
| |
|---|---|---|---|---|
| ( | ( | ( | ||
| BIVA data | ||||
| Hydration, % | 71.0 (64.2–72.6) | 73.5 (73.2–73.9) | 85.2 (78.4–89.0) | <0.001 |
| Resistance/height, Ω/m | 321 (249–348) | 314 (257–351) | 224 (188–267) | 0.002 |
| Reactance/height, Ω/m | 43.6 (40.7–58.9) | 29.6 (26.4–33.9) | 16.5 (11.5–20.4) | <0.001 |
| Phase angle, degrees | 9.1 (7.3–10.3) | 5.5 (5.2–6.3) | 3.8 (3.0–4.4) | <0.001 |
| Haemodynamic data | ||||
| Mean arterial pressure, mmHg | 71 (67–76) | 78 (70–92) | 71 (67–78) | 0.13 |
| Central venous pressure, mmHg | 11 (8–12) | 10 (8–12) | 12 (10–14) | 0.08 |
| Missing observations, | 3 | 9 | 0 | |
| Noradrenaline, μg/min | 3.5 (0–6) | 0 (0–2) | 6 (1–10) | 0.04 |
| Oxygen exchange | ||||
| FiO2, % | 0.40 (0.25–0.50) | 0.30 (0.21–0.40) | 0.30 (0.21–0.40) | 0.28 |
| PaO2, mmHg | 82 (67–98) | 105 (75–122) | 82 (72–97) | 0.07 |
| PaO2/FiO2 ratio, mmHg | 249 (166–300) | 334 (273–407) | 316 (236–419) | 0.06 |
| Biochemical data | ||||
| Creatinine, μmol/L | 72 (55–131) | 70 (40–100) | 116 (73–160) | 0.03 |
| Missing observations, | 1 | 0 | 0 | |
| Sodium, mmol/L | 138 (134–142) | 137 (135–140) | 137 (135–139) | 0.97 |
| Lactate, mmol/L | 1.6 (1.1–2.2) | 1.5 (1.1–2.4) | 1.9 (1.4–2.5) | 0.45 |
BIVA bioelectrical impedance vector analysis, FiO fraction of inspired oxygen, PaO partial pressure of arterial oxygen
Continuous variables are presented as median (interquartile range)
aStatistical comparisons of the data were performed using the Kruskal-Wallis test
Fig. 3Cumulative fluid balance during the first 4 days in the intensive care unit (ICU) in patients with dehydration, normal hydration and overhydration on admission. Values are mean ± SE. BIVA bioelectrical impedance vector analysis
Fig. 4Mean daily hydration determined by bioelectrical impedance vector analysis (BIVA) in patients with dehydration (a), normal hydration (b) and overhydration (c) upon admission. P values represent repeated-measures analysis of variance for change in hydration level over time
Changes in hydration determined by bioelectrical impedance vector analysis in patients with different magnitude changes in cumulative fluid balance
| First measurement | Second measurementa | Change between first and second measurement |
| |
|---|---|---|---|---|
| ≥1-L positive fluid balance, | ||||
| Cumulative fluid balance, ml | 0 (0) | 1385 (1205–2022) | 1385 (1205–2022) | |
| Study day | 0 (0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | |
| Central venous pressure, mmHg | 12 (10–13) | 12 (8–15) | 0 (−3 to 3) | 0.84 |
| Missing observations, | 7 | 7 | 7 | |
| Lactate, mmol/L | 2 (1.1–3.3) | 1.7 (1.5–2.5) | −0.3 (−0.6, 0.4) | 0.67 |
| BIVA hydration, % | 73.8 (72.6–82.1) | 79.7 (72.9–86.0) | 1.5 (−0.8 to 7.0) | 0.09 |
| ≥2-L positive fluid balance, | ||||
| Cumulative fluid balance, ml | 0 (0) | 2419 (2196–2696) | 2419 (2196–2696) | |
| Study day | 0 (0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | |
| Central venous pressure, mmHg | 12 (10–14) | 13 (11–17) | 1.5 (0–3) | 0.14 |
| Missing observations, | 5 | 5 | 5 | |
| Lactate, mmol/L | 2.2 (1.2–3.7) | 2 (1.7–2.4) | 0.3 (0.2–0.7) | 0.38 |
| BIVA hydration, % | 73.1 (72.6–73.9) | 73.8 (73.3–80.3) | 0.7 (0–6.4) | 0.09 |
| ≥1-L negative fluid balance, | ||||
| Cumulative fluid balance, ml | 0 (0) | −1553 (−2056 to -1297) | −1553 (−2056 to −1297) | |
| Study day | 0 (0) | 1.5 (0.5–2.5) | 1.5 (0.5–2.5) | |
| Central venous pressure, mmHg | 11 (10–14) | 12 (9–15) | 0 (-2.5, 2) | 0.72 |
| Missing observations, | 3 | 3 | 3 | |
| Lactate, mmol/L | 1.5 (1.1–2.4) | 1.6 (1.2–2.1) | 0.1 (−0.4, 0.5) | 0.88 |
| BIVA hydration, % | 77.3 (73.0–89.0) | 76.5 (73.0–85.2) | −0.3 (−4.5 to 0.7) | 0.22 |
| ≥2-L negative fluid balance, | ||||
| Cumulative fluid balance, ml | 0 (0) | −2426 (−2606 to −2228) | -2426 (−2606 to −2228) | |
| Study day | 0 (0) | 1.5 (1.0–2.5) | 1.5 (1.0–2.5) | |
| Central venous pressure, mmHg | 11 (10–13) | 10 (8–12) | −2 (−5, 0) | 0.11 |
| Missing observations, | 2 | 2 | 2 | |
| Lactate, mmol/L | 2 (1.1–2.4) | 1.5 (1.2–2.3) | −0.1 (−0.6, 0.3) | 0.53 |
| BIVA hydration, % | 77.3 (73.3–88.3) | 73.9 (72.7–85.2) | −0.8 (−3.4 to −0.1) | 0.02 |
BIVA bioelectrical impedance vector analysis
Continuous variables are presented as median (interquartile range)
aSecond measurement refers to the time when the pre-determined cumulative fluid balance was reached
bChange between the first and second measurement assessed by nonparametric Wilcoxon signed rank test
Fig. 5Changes in hydration determined by bioelectrical impedance vector analysis (BIVA) (a), central venous pressure (CVP) (b) and lactate (c) versus changes in cumulative fluid balance and changes in BIVA hydration versus changes in lactate (d) between the time points of the first and last BIVA recordings
Outcome data
| All | Dehydration | Normal | Overhydration |
| |
|---|---|---|---|---|---|
| ( | ( | ( | ( | ||
| Renal replacement therapy | 8 (13 %) | 2 (14 %) | 2 (9 %) | 4 (16 %) | 0.80 |
| ICU length of stay, days | 5.1 (3.5–10) | 6.1 (3.9–7.3) | 4.7 (2.8–12) | 7.0 (3.5–9.6) | 0.87 |
| Hospital length of stay, days | 16 (7.9–30) | 13 (7.6–21) | 15 (7.3–32) | 22 (11–36) | 0.22 |
| ICU mortality | 7 (11 %) | 2 (14 %) | 2 (9 %) | 3 (12 %) | 0.89 |
| Hospital mortality | 12 (20 %) | 4 (29 %) | 3 (14 %) | 5 (20 %) | 0.55 |
ICU intensive care unit
Data are medians (interquartile range) or n (%)